Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.
Zamboglou C, Drendel V, Jilg CA, Rischke HC, Beck TI, Schultze-Seemann W, Krauss T, Mix M, Schiller F, Wetterauer U, Werner M, Langer M, Bock M, Meyer PT, Grosu AL. Zamboglou C, et al. Among authors: grosu al. Theranostics. 2017 Jan 1;7(1):228-237. doi: 10.7150/thno.16638. eCollection 2017. Theranostics. 2017. PMID: 28042330 Free PMC article.
Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference.
Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, Mix M, Schiller F, Mavroidis P, Meyer PT, Werner M, Grosu AL, Baltas D. Zamboglou C, et al. Among authors: grosu al. Radiother Oncol. 2017 Jun;123(3):472-477. doi: 10.1016/j.radonc.2017.04.021. Epub 2017 May 9. Radiother Oncol. 2017. PMID: 28499607
The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer.
Zamboglou C, Klein CM, Thomann B, Fassbender TF, Rischke HC, Kirste S, Henne K, Volegova-Neher N, Bock M, Langer M, Meyer PT, Baltas D, Grosu AL. Zamboglou C, et al. Among authors: grosu al. Radiat Oncol. 2018 Apr 12;13(1):65. doi: 10.1186/s13014-018-1014-1. Radiat Oncol. 2018. PMID: 29650029 Free PMC article.
Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference.
Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL. Zamboglou C, et al. Among authors: grosu al. Radiat Oncol. 2018 May 2;13(1):81. doi: 10.1186/s13014-018-1036-8. Radiat Oncol. 2018. PMID: 29716617 Free PMC article.
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL. Wiedenmann N, et al. Among authors: grosu al. Radiat Oncol. 2018 Sep 21;13(1):183. doi: 10.1186/s13014-018-1134-7. Radiat Oncol. 2018. PMID: 30241555 Free PMC article.
Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference.
Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, Bronsert P, Koeber G, Schilling O, Ruf J, Werner M, Jilg CA, Baltas D, Mix M, Grosu AL. Zamboglou C, et al. Among authors: grosu al. Theranostics. 2019 Apr 13;9(9):2595-2605. doi: 10.7150/thno.32376. eCollection 2019. Theranostics. 2019. PMID: 31131055 Free PMC article.
434 results